Navigation Links
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Date:11/24/2009

ard of Directors, commented, "On behalf of the NeurogesX board, I would like to welcome John as our newest director. John has a successful track record introducing new therapeutics to the market, and we look forward to his contributions and insights as we focus on the upcoming launch of Qutenza(TM) in the United States and Europe. Strong sales and marketing capabilities are the foundation for a successful product launch, and the addition of John to the Board of Directors will be of significant value as the board and management team work together to ensure the success of the Qutenza brand."

Mr. Orwin said, "Launching a new product creates a significant growth opportunity, and Qutenza has great potential to deliver substantial value to patients, physicians and NeurogesX. The board and management team have executed an impressive clinical and regulatory strategy for Qutenza on par with biopharmaceutical industry leaders. I look forward to joining the board and advising on the commercial infrastructure and upcoming launch."

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead

product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza(TM) (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
2. NeurogesX Expands Commercial Operations Leadership Team
3. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
4. NeurogesX to Present at JMP Securities Healthcare Focus Conference
5. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
6. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
9. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
10. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oct. 31, 2014  Zebra Imaging, Inc., the ... announced today a strategic partnership with the Zygote ... 3D anatomy and biomedical models for animation and ... education markets.  Zygote maintains the world,s most comprehensive ... and has pioneered development of high-end solid 3D ...
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)...  Zacks.com announces the list of stocks featured in the Analyst ... news and events impacting stocks and the financial markets. Stocks recently ... - Free Report ), Celgene (Nasdaq: CELG - ... Free Report ), Market Vectors Biotech ETF (AMEX: BBH ... XBI - Free Report ). Today, ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
... Secondary Endpoints, San Carlos, Calif., Sept. 4 ... company focused on developing novel,pain management therapies, today ... of NGX-4010, the Company,s dermal patch containing,the TRPV1 ... postherpetic,neuralgia (PHN). The study, a multi-center, double-blind, controlled ...
Cached Medicine Technology:Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 2NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 4NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 5NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 6NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 7
(Date:10/31/2014)... October 31, 2014 This Method ... amazing health effects for practitioners. , The ... Doctor of Science and Movement specializing in physical ... to pelvic floor reeducation that traditional abdominal exercises ... Diastasis Recti, Prolepses, etc. , The Hipopressives exercises ...
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Surgery for low back ... in the United States you live, a new report ... low back pain at some point in their lives, ... medical care for a spine problem," co-author Brook Martin, ... Practice, said in a college news release. In ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... Urban Hydroponics, Inc. (OTCQB:URHY), a Nevada ... has signed a Binding Letter of Intent (LOI) to ... sector - Urban Cultivator Inc. (“Urban Cultivator”), BC Northern ... Inc. (“W3 Metal” and together with Urban Cultivator and ... the LOI and an earlier non-binding term sheet, Urban ...
(Date:10/31/2014)... Miami, FL (PRWEB) October 31, 2014 ... recently volunteered his hair restoration services to transform the ... part of the American Academy of Facial Plastic and ... donated his time to restore the facial hair Jones ... , The pro-bono hair restoration procedure, valued ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2
... $18 million research program headed by Washington University ... and diagnostic tools for heart and lung diseases ... Heart, Lung, and Blood Institute, will fund five ... collaborating,institutions: Texas A&M University, University of Texas Southwestern ...
... The Alzheimer,s Association has awarded a three-year, $200,000 ... The University of Texas Health Science Center at Houston ... Alzheimer,s disease. "The main goal of this project ... such as a blood test that can tell people ...
... A team of researchers led by a Michigan State University ... for breast cancer in young women, focusing on growth, diet, ... The five-year study, funded by the National Institutes ... of Human Medicine,s Department of Epidemiology, will include the largest ...
... traumatic event a car accident, a physical or ... many as 1 in 5 children will develop Posttraumatic ... helps improve communication between child and caregiver, such as ... skills, was able to prevent chronic and sub-clinical PTSD ...
... Minn. -- In the largest, most modern, single-institution ... a long-term data registry for survival rates of ... for localized prostate cancer. The findings are being ... American Urological Association,s 84th Annual Meeting in Chicago. ...
... HealthDay Reporter , TUESDAY, Sept. 28 (HealthDay News) -- ... proteins may indicate the presence of prostate cancer more accurately ... The test, which has thus far only been assessed ... fewer false-positive results than the prostate specific antigen (PSA) test, ...
Cached Medicine News:Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 2Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 3Health News:MSU researcher awarded $14 million to identify breast cancer risk factors 2Health News:After traumatic event, early intervention reduces odds of PTSD in children by 73 percent 2Health News:Surgery offers long-term survival for early stage prostate cancer patients 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 3
The Hypervisor VI is a solution for telemetry, LAN and wireless LAN networking. It includes bi-directional communication with Mindray bedside patient monitors and can store waveforms and numeric info...
DS 7600 Central Station...
... DLE (Drug List Editor) Multi-Channel Infusion System ... technology. The instrument combines three independent infusion ... in an unparalleled small size. Now with ... Infusion System simplifies the delivery of complex ...
... SRS Freedom Chart Manager provides powerful workflow ... order management, integrated transcription services, and customized ... engine that eliminates the need for paper ... benefits of a paperless office now and ...
Medicine Products: